Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study.
Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study.
复制标题
胸腺肽 Alpha 1 治疗 COVID-19 的功效：一项多中心队列研究
DOI：
10.3389/fimmu.2021.673693
复制
发表时间：
2021
影响因子：
7.3
通讯作者：
Chen D
中科院分区：
文献类型：
--
作者：
Liu J;Shen Y;Wen Z;Xu Q;Wu Z;Feng H;Li Z;Dong X;Huang S;Guo J;Zhang L;Chen Y;Li W;Zhu W;Du H;Liu Y;Wang T;Chen L;Teboul JL;Annane D;Chen D
在中国，胸腺素α 1（Tα1）被广泛用于治疗COVID-19患者;然而，其疗效仍不清楚。本研究旨在探索Tα1作为COVID-19治疗的有效性。我们于2019年12月至2020年3月在中国湖北省的五家三级医院进行了一项多中心队列研究。患者未痊愈率被用作主要结局。所有原油产出，包括未采收率（65/306 vs. 290/1，976，p = 0.003），住院死亡率（62/306 vs. 271/1，976，p = 0.003），插管率（31/306 vs. 106/1，976，p = 0.001），急性呼吸窘迫综合征（ARDS）发生率（104/306 vs. 499/1，976，p = 0.001），急性肾损伤（阿基）发生率（26/306 vs. 66/1，976，p < 0.001）和重症监护室（ICU）住院时间（14.9 ± 12.7 vs. 8.7 ± 8.2天，p < 0.001）显著高于Tα1治疗组。在调整混杂因素后，发现使用Tα1与非T α1使用相比更高的未恢复率显著相关（OR 1.5，95% CI 1.1-2.1，p = 0.028）。在最大序贯器官衰竭评估（SOFA）评分≥2的患者亚组中，观察到与Tα1使用相关的未恢复率风险增加（OR 2.0，95%CI 1.4-2.9，p = 0.024），ICU入院记录（OR 5.4，95%CI 2.1-14.0，p < 0.001），PaO 2/FiO 2值较低（OR 1.9，95%CI 1.1-3.4，p = 0.046）。此外，较晚开始使用Tα1与较高的未恢复率相关。在COVID-19患者中使用Tα1与未恢复率增加相关，尤其是在疾病严重程度较高的患者中。
Thymosin alpha 1 (Tα1) is widely used to treat patients with COVID-19 in China; however, its efficacy remains unclear. This study aimed to explore the efficacy of Tα1 as a COVID-19 therapy. We performed a multicenter cohort study in five tertiary hospitals in the Hubei province of China between December 2019 and March 2020. The patient non-recovery rate was used as the primary outcome. All crude outcomes, including non-recovery rate (65/306 vs. 290/1,976, p = 0.003), in-hospital mortality rate (62/306 vs. 271/1,976, p = 0.003), intubation rate (31/306 vs. 106/1,976, p = 0.001), acute respiratory distress syndrome (ARDS) incidence (104/306 vs. 499/1,976, p = 0.001), acute kidney injury (AKI) incidence (26/306 vs. 66/1,976, p < 0.001), and length of intensive care unit (ICU) stay (14.9 ± 12.7 vs. 8.7 ± 8.2 days, p < 0.001), were significantly higher in the Tα1 treatment group. After adjusting for confounding factors, Tα1 use was found to be significantly associated with a higher non-recovery rate than non-Tα1 use (OR 1.5, 95% CI 1.1–2.1, p = 0.028). An increased risk of non-recovery rate associated with Tα1 use was observed in the patient subgroups with maximum sequential organ failure assessment (SOFA) scores ≥2 (OR 2.0, 95%CI 1.4–2.9, p = 0.024), a record of ICU admission (OR 5.4, 95%CI 2.1–14.0, p < 0.001), and lower PaO2/FiO2 values (OR 1.9, 95%CI 1.1–3.4, p = 0.046). Furthermore, later initiation of Tα1 use was associated with a higher non-recovery rate. Tα1 use in COVID-19 patients was associated with an increased non-recovery rate, especially in those with greater disease severity.
登录
查看更多内容
影响因子：
5.6
作者：
Shao, Congwen;Tian, Guojun;Zeng, Weisen
通讯作者：
Zeng, Weisen
DOI：
10.1016/j.dsx.2020.07.011
发表时间：
2020-09-01
影响因子：
10
作者：
Subir, Ray;Jagat, Mukherjee J.;Kalyan, Gangopadhyay K.
通讯作者：
Kalyan, Gangopadhyay K.
影响因子：
168.9
作者：
Huang, Chaolin;Wang, Yeming;Cao, Bin
通讯作者：
Cao, Bin
中国武汉市 138 例 2019 新型冠状病毒感染肺炎住院患者的临床特征。
影响因子：
120.7
作者：
Wang, Dawei;Hu, Bo;Peng, Zhiyong
通讯作者：
Peng, Zhiyong
影响因子：
82.9
作者：
Romani L;Oikonomou V;Moretti S;Iannitti RG;D'Adamo MC;Villella VR;Pariano M;Sforna L;Borghi M;Bellet MM;Fallarino F;Pallotta MT;Servillo G;Ferrari E;Puccetti P;Kroemer G;Pessia M;Maiuri L;Goldstein AL;Garaci E
通讯作者：
Garaci E